Patents by Inventor Scott Hauenstein
Scott Hauenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220096629Abstract: The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNF? inhibitor for the treatment of a TNF?-mediated disease or disorder.Type: ApplicationFiled: September 24, 2021Publication date: March 31, 2022Inventors: Sharat Singh, Nicholas Hoe, Steve Lockton, Scott Hauenstein, Linda Ohrmund
-
Patent number: 11160863Abstract: The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNF? inhibitor for the treatment of a TNF?-mediated disease or disorder.Type: GrantFiled: August 24, 2018Date of Patent: November 2, 2021Assignee: PROMETHEUS LABORATORIES INC.Inventors: Sharat Singh, Nicholas Hoe, Steve Lockton, Scott Hauenstein, Linda Ohrmund
-
Patent number: 10794906Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.Type: GrantFiled: September 1, 2016Date of Patent: October 6, 2020Assignee: Prometheus Biosciences, Inc.Inventors: Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
-
Publication number: 20190060449Abstract: The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNF? inhibitor for the treatment of a TNF?-mediated disease or disorder.Type: ApplicationFiled: August 24, 2018Publication date: February 28, 2019Applicant: Nestec S.A.Inventors: Sharat Singh, Nicholas Hoe, Steve Lockton, Scott Hauenstein, Linda Ohrmund
-
Patent number: 10086072Abstract: The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNF? inhibitor for the treatment of a TNF?-mediated disease or disorder.Type: GrantFiled: November 5, 2013Date of Patent: October 2, 2018Assignee: Nestec S.A.Inventors: Sharat Singh, Nicholas Hoe, Steve Lockton, Scott Hauenstein, Linda Ohrmund
-
Patent number: 9784748Abstract: The present invention provides assay methods for the determination of one or more anti-drug antibody (ADA) isotypes in a sample. As a non-limiting example, the assays of the present invention are particularly useful for determining different ADA isotypes in samples from ADA-positive patients receiving an anti-TNF? drug such as REMICADE™ (infliximab) or HUMIRA™ (adalimumab). The present invention also provides methods for optimizing therapy and/or reducing toxicity in subjects receiving TNF? inhibitors for the treatment of TNF?-mediated disease or disorders.Type: GrantFiled: April 17, 2013Date of Patent: October 10, 2017Assignee: NESTEC S.A.Inventors: Shui Long Wang, Linda Ohrmund, Scott Hauenstein, Sharat Singh
-
Publication number: 20170176433Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.Type: ApplicationFiled: September 1, 2016Publication date: June 22, 2017Applicant: NESTEC S.A.Inventors: Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
-
Patent number: 9465027Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.Type: GrantFiled: December 30, 2013Date of Patent: October 11, 2016Assignee: Nestec S.A.Inventors: Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
-
Publication number: 20150355195Abstract: The present invention provides methods for predicting the likelihood of mucosal healing in an individual with a disease such as inflammatory bowel disease (IBD). In addition, the present invention provides methods for monitoring the progression of mucosal healing in an individual with a disease such as IBD. Information on mucosal healing status derived from the use of the present invention can also aid in optimizing therapy and/or monitoring the therapeutic efficiency of an anti-TNF? inhibitor drug.Type: ApplicationFiled: April 3, 2015Publication date: December 10, 2015Applicant: NESTEC S.A.Inventors: Sharat Singh, Xinjun Liu, Scott Hauenstein, Richard Kirkland, Katherine Drake
-
Publication number: 20140186973Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.Type: ApplicationFiled: December 30, 2013Publication date: July 3, 2014Applicant: NESTEC S.A.Inventors: Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
-
Publication number: 20140141983Abstract: The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNF? inhibitor for the treatment of a TNF?-mediated disease or disorder.Type: ApplicationFiled: November 5, 2013Publication date: May 22, 2014Applicant: NESTEC S.A.Inventors: Sharat Singh, Nicholas Hoe, Steve Lockton, Scott Hauenstein, Linda Ohrmund
-
Publication number: 20140051184Abstract: The present invention provides assays for detecting and measuring the presence or level anti-TNF? drugs and/or the autoantibodies to anti-TNF? drugs in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and/or reducing toxicity in subjects receiving anti-TNF? drugs for the treatment of TNF?-mediated disease or disorders.Type: ApplicationFiled: March 12, 2013Publication date: February 20, 2014Inventors: Sharat Singh, Scott Hauenstein, Linda Ohrmund
-
Publication number: 20140045276Abstract: The present invention provides assays for detecting and measuring the presence or level of autoantibodies to anti-TNF? drug therapeutics in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and/or reducing toxicity in subjects receiving anti-TNF? drugs for the treatment of TNF?-mediated disease or disorders.Type: ApplicationFiled: August 7, 2013Publication date: February 13, 2014Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund, Scott Hauenstein
-
Publication number: 20130266963Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.Type: ApplicationFiled: March 13, 2013Publication date: October 10, 2013Inventors: Scott Hauenstein, Sharat Singh